| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced new data on its CAPTN-3 tri-specific antibody IM1240 generated in the laboratory of Dr. Amir Horowitz of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.
"The collaboration with Dr. Horowitz, a leading expert in cancer immunology and immunotherapy, enables us to evaluate the effects of the CAPTN-3 antibody on patient-derived tumor biopsies, where tumor cell heterogeneity, the immune cell array and other tumor microenvironment (TME) components are preserved, providing a reliable representation of the clinical condition of a patient. Dr. Horowitz's research is assessing the efficacy and mechanism of action of the CAPTN-3 antibody in several cancer types, including treatment-resistant Non-Small Cell Lung Cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and bladder cancer, which represent areas of significant unmet medical need," said Gil Efron, CEO of Purple Biotech.
Using fresh biopsies of HNSCC patients who have acquired resistance to anti-PD1 therapy, Dr. Horowitz's results have shown induction of cancer cell apoptosis by the tri-specific IM1240 (capped-CD3x5T4xNKG2A), while none of the related variant bispecifics, having either a non-functional CD3 arm (5T4xCD3) or NKG2A arm (5T4xNKG2A), showed an effect. The results correlate with patient-derived NSCLC tumor explants previously reported and suggest a synergistic effect of the CD3 and the NKG2A arms, a design which is unique to Purple's CAPTN-3 platform.
"Targeting NKG2A offers a selective checkpoint inhibition strategy that enhances antitumor cytotoxicity while minimizing off-target immune activation. The selective expression of NKG2A mainly on cytotoxic lymphocytes such as Natural Killer (NK) cells and CD8⁺ cytotoxic T cells (CTLs), makes NKG2A blockade a potentially safer approach compared with other checkpoint inhibitors, and a complementary therapy which acts synergistically with the CD3 engager function of CAPTN-3" commented Dr. Horowitz. "Additionally, robust data analysis representing of approximately 26,000 human transcriptomes across most solid tissues suggests that NKG2A expression is consistently accompanied by both HLA-E and 5T4 in solid tissues, but not in blood, supporting the design of IM1240 that targets 5T4 and potentially reducing safety concerns."
Posted In: PPBT
